Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. - Wikidata - thesis-toulmin - TriplyDB

Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial.

Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial.

http://www.wikidata.org/entity/Q34555503

about

Anti-angiogenic therapies for metastatic colorectal cancer Advances of Targeted Therapy in Treatment of Unresectable Metastatic Colorectal Cancer Therapeutic strategy in unresectable metastatic colorectal cancer: an updated review Effectiveness and safety of monoclonal antibodies for metastatic colorectal cancer treatment: systematic review and meta-analysis The Crossroads of Geriatric Cardiology and Cardio-Oncology Anti-angiogenic agents in metastatic colorectal cancer Addition of bevacizumab to first-line chemotherapy in advanced colorectal cancer: a systematic review and meta-analysis, with emphasis on chemotherapy subgroups Management of colorectal cancer The impact of Bevacizumab (Avastin) on survival in metastatic solid tumors--a meta-analysis and systematic review Value of bevacizumab in treatment of colorectal cancer: A meta-analysis Review of systemic therapies for locally advanced and metastatic rectal cancer Management of locally advanced and metastatic colon cancer in elderly patients Relationship between hypoxia and response to antiangiogenic therapy in metastatic colorectal cancer Multisciplinary management of patients with liver metastasis from colorectal cancer Gastrointestinal Toxicities With Combined Antiangiogenic and Stereotactic Body Radiation Therapy Front-line bevacizumab in combination with oxaliplatin, leucovorin and 5-fluorouracil (FOLFOX) in patients with metastatic colorectal cancer: a multicenter phase II study Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab Angiogenesis inhibitor bevacizumab increases the risk of ischemic heart disease associated with chemotherapy: a meta-analysis Increased risk of hemorrhage in metastatic colorectal cancer patients treated with bevacizumab: An updated meta-analysis of 12 randomized controlled trials.Meta-analysis of cardiovascular toxicity risks in cancer patients on selected targeted agents.Oral drugs in the treatment of metastatic colorectal cancer.Targeting the vascular endothelial growth factor pathway in the treatment of human malignancy.Effectiveness of bevacizumab with first-line combination chemotherapy for Medicare patients with stage IV colorectal cancer.Targeted therapies in metastatic colorectal cancer: a systematic review and assessment of currently available data Bevacizumab with chemotherapy in patients with KRAS wild-type metastatic colorectal cancer: Czech registry data.Bevacizumab combined with chemotherapy for patients with advanced colorectal cancer: a systematic review.Effect of angiogenesis inhibitor bevacizumab on survival in patients with cancer: a meta-analysis of the published literature.Safety of bevacizumab in treating metastatic colorectal cancer: a systematic review and meta-analysis of all randomized clinical trials.An updated meta-analysis of fatal adverse events caused by bevacizumab therapy in cancer patients.Importance of response to neoadjuvant chemotherapy in potentially curable colorectal cancer liver metastases.Safety of bevacizumab in patients with advanced cancer: a meta-analysis of randomized controlled trials.Pooled safety and efficacy analysis examining the effect of performance status on outcomes in nine first-line treatment trials using individual data from patients with metastatic colorectal cancer The role of anti-VEGF agents in the treatment of advanced gastric cancer: a meta-analysis of randomized controlled trials.Strategies of sequential therapies in unresectable metastatic colorectal cancer: a meta-analysis.Potential role of vascular targeted therapy to combat against tumor.Bevacizumab plus FOLFIRI or FOLFOX in chemotherapy-refractory patients with metastatic colorectal cancer: a retrospective study Adrenomedullin as a therapeutic target in angiogenesis.Multidisciplinary approach of colorectal cancer liver metastases.Risk of high-grade bleeding in patients with cancer treated with bevacizumab: a meta-analysis of randomized controlled trials.Cardio-Oncology: Cancer Therapy-related Cardiovascular Complications in a Molecular Targeted Era: New Concepts and Perspectives.

P2860

Q24241813-04EB956F-F09D-4AAC-B62F-599E43B21E6B Q26748924-E93D24F9-DCCA-4879-B9F1-BB3BF49DD75D Q26775522-EC78F7C2-71A6-4CD5-A22D-51654F6121DA Q26777704-D57CE6DF-5EDF-400A-B879-4449B59C3B47 Q26778666-D54FCBED-E95C-4D4A-93F3-753E87A78C0C Q26801911-95567151-E7CF-4B0B-8198-209A29333EEC Q26822395-28015B21-B3CE-4CC0-B864-D3458C618181 Q26823550-265EC7BA-B3BA-47A4-B976-907C49AB1A71 Q26824086-3DC6049D-A328-4D14-B9A9-1DA37B84144F Q26849789-9D433201-F758-4CC4-B702-E8F0C9F141F7 Q27021105-2B2723D9-9DB7-49DC-AE44-7C5581D1ADB1 Q27026129-6583F453-8737-4E3C-9AF8-364D1AF9897B Q28068654-468365C6-3EE9-4212-A192-27C139FFCE92 Q28069575-3148F5FB-2EB4-480A-A5AB-9353985BF32C Q28086904-89C51ED2-CEAE-4D73-B09C-7CAEEC66061E Q28211801-1E0D532D-2A60-4534-BDE1-10EA40E49458 Q28219257-AAA96A72-48BD-46E3-910C-362E029D956C Q28534015-009023AC-2AB2-440D-A301-855A1AA05A99 Q30248296-F7BD8EA5-5274-4AED-8AD2-57AAA0773025 Q30249335-F31306B2-B8EF-4493-A20D-615B0162D409 Q30251387-382552E8-BCEE-4888-BAA7-43F512DFB477 Q30358961-9D4678FE-149F-4805-91B4-FC9D8E459943 Q30422372-3F59C004-E164-4AED-9F0F-87BC502D79AD Q30862367-2E96E0E8-BB66-4572-9243-D216F5B8173A Q30884552-5685B4B3-A4FE-4B72-8D4A-DA695B588C83 Q30922171-B03B4FA0-2527-4B4C-B9B2-9AE2853B67DA Q31060162-CA76BCB1-51A5-4104-ACF9-25BC0FFF95C0 Q31127134-F693A7E4-D7D6-40D7-B039-7A499721A3AE Q31152878-8FDD3FEB-9348-4BEC-9DA5-73EDCB088CEA Q33330997-83C45046-0D51-4C86-8EAB-4BB8CEC8C7F6 Q33392652-423394C5-7F3A-4843-9C22-CC2DFF39DCC2 Q33414068-9BAC5A30-6E1B-4639-9BC0-2E5EB68C564C Q33415118-CAC323C9-4AD3-41EF-AC0A-AD446412B5C0 Q33419230-7C2266B9-2431-4560-AEC0-CB7F58386A80 Q33470615-ECB9343E-D78D-4765-B23B-BCA52A8CE49F Q33507171-5C2F9C94-5B4C-4763-B1F6-AB96629389AE Q33693793-4EF9827D-D554-461B-AA3B-E12397129A3F Q33779859-EECDAD53-E075-4367-BFA1-9D9B078274D2 Q33795896-382B5966-4A4A-4094-8030-41FD65A32C72 Q33807542-C6C040C4-1A19-41FE-9035-F31277C52D81

P2860

Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial.

http://www.wikidata.org/entity/Q34555503

description

2005 nî lūn-bûn

@nan

2005 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

Addition of bevacizumab to bol ...... f a randomized phase II trial.

@ast

Addition of bevacizumab to bol ...... f a randomized phase II trial.

@en

Addition of bevacizumab to bol ...... f a randomized phase II trial.

@nl

type

label

Addition of bevacizumab to bol ...... f a randomized phase II trial.

@ast

Addition of bevacizumab to bol ...... f a randomized phase II trial.

@en

Addition of bevacizumab to bol ...... f a randomized phase II trial.

@nl

prefLabel

Addition of bevacizumab to bol ...... f a randomized phase II trial.

@ast

Addition of bevacizumab to bol ...... f a randomized phase II trial.

@en

Addition of bevacizumab to bol ...... f a randomized phase II trial.

@nl

P1433

Q34555503-A74C5B98-00A7-4A9C-BC66-C92C2630ED7D

P1476

Q34555503-D91E5A08-5497-49FB-A863-EA27BE45C6DD

P2093

Q34555503-146DAF74-15A9-4A46-BD99-27B3139000F8

Q34555503-170867A8-68CA-46D3-9048-F4B8CDF997B8

Q34555503-2328FEF8-4664-42CF-A339-92B996A06379

Q34555503-34FD03D0-3AD7-4CC8-9268-22FF00A15318

Q34555503-49B66B28-8DB0-4DB0-86AD-CCF3F77B632D

Q34555503-775AE604-E2AC-4305-BECA-A73ED409A9E8

Q34555503-943EEEF9-8DC8-44BE-9C1A-6A242DDA008C

Q34555503-C9AB0921-89A6-4C20-B0A0-B6198B2A05C4

Q34555503-D6C5776B-612C-4236-ABC7-D5CC7F01C0D1

Q34555503-D9C561EB-14CC-4B5D-A6AE-07927C75BC01

P304

Q34555503-4A8ABB19-2A35-4434-9E16-1C81E6434EAF

P31

Q34555503-19395B93-A21B-4B0D-9591-7D7F6ADF7065

P356

Q34555503-EFBBE214-B609-4D17-B834-9057FA6052F4

P407

Q34555503-7363F261-D269-4F12-A1CE-78BBFFF4D87C

P433

Q34555503-F7B18E6A-FC99-40FD-ABA5-0735F1BDAFBA

P478

Q34555503-604DFBBA-F9DC-478F-94D6-4E0A2110313B

P577

Q34555503-CDDACA8B-6288-4715-AA27-7EF123251A9E

P698

Q34555503-B318A691-1C2F-4E44-B3EF-D7D7B78C6A14

P921

Q34555503-31119FFD-39A4-43E4-A903-DCC77595A96A

Q34555503-6069C34C-AE63-4778-867B-A3213F5DFA70

Q34555503-99F5BC10-3764-4655-B9DC-66C068C35C70

P356

JCO.2005.05.112

P1433

Journal of Clinical Oncology

P1476

Addition of bevacizumab to bol ...... f a randomized phase II trial.

@en

P2093

Betty Nelson

http://www.w3.org/2001/XMLSchema#string

Brent Perrou

http://www.w3.org/2001/XMLSchema#string

Fairooz F Kabbinavar

http://www.w3.org/2001/XMLSchema#string

J Randolph Hecht

http://www.w3.org/2001/XMLSchema#string

John T Hamm

http://www.w3.org/2001/XMLSchema#string

Joseph Schulz

http://www.w3.org/2001/XMLSchema#string

Michael McCleod

http://www.w3.org/2001/XMLSchema#string

Robert Mass

http://www.w3.org/2001/XMLSchema#string

Taral Patel

http://www.w3.org/2001/XMLSchema#string

William F Novotny

http://www.w3.org/2001/XMLSchema#string

P304

3697-3705

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2005.05.112

http://www.w3.org/2001/XMLSchema#string

P407

P433

16

http://www.w3.org/2001/XMLSchema#string

P478

23

http://www.w3.org/2001/XMLSchema#string

P577

2005-02-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15738537

http://www.w3.org/2001/XMLSchema#string

P921

colorectal cancer

phase II clinical trial